Oric Pharmaceuticals (ORIC) Equity Ratio (2019 - 2026)
Oric Pharmaceuticals filings provide 8 years of Equity Ratio readings, the most recent being 0.95 for Q1 2026.
- Quarterly Equity Ratio rose 5.16% to 0.95 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.95 through Mar 2026, up 5.16% year-over-year, with the annual reading at 0.94 for FY2025, 5.99% up from the prior year.
- Equity Ratio hit 0.95 in Q1 2026 for Oric Pharmaceuticals, up from 0.94 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.95 in Q1 2026 and bottomed at 0.89 in Q4 2024.
- Average Equity Ratio over 5 years is 0.92, with a median of 0.91 recorded in 2022.
- The largest annual shift saw Equity Ratio decreased 5.36% in 2022 before it grew 5.99% in 2025.
- Oric Pharmaceuticals' Equity Ratio stood at 0.9 in 2022, then fell by 1.15% to 0.89 in 2023, then dropped by 0.27% to 0.89 in 2024, then rose by 5.99% to 0.94 in 2025, then grew by 1.22% to 0.95 in 2026.
- Per Business Quant, the three most recent readings for ORIC's Equity Ratio are 0.95 (Q1 2026), 0.94 (Q4 2025), and 0.94 (Q3 2025).